Neuroleptic Malignant Syndrome: A Focus on Risk, Recognition and Antipsychotic Re-Challenge

Tobias Rowland* and Cornelia Beyers
1Warwick Medical School, University of Warwick, UK
2Coventry and Warwickshire Partnership Trust, The Caludon Centre, UK

Keywords: Neuroleptic malignant syndrome; Risk factors; Management

Introduction

Neuroleptic Malignant Syndrome (NMS) is a potentially fatal adverse drug reaction, most commonly to antipsychotic medications, characterised by muscle rigidity, hyperthermia, delirium and autonomic instability. Although NMS is relatively uncommon, with an estimated incidence of around 0.9% of those on antipsychotic medications over an 18 month period [1], the estimated mortality has been reported between 5.6% to 12% [2,3] and therefore prompt treatment is essential.

Risk Factors

Identifying clinical risk factors for NMS enables clinicians to recognise those individuals most likely to develop the syndrome. Several authors have previously studied the risk factors for developing NMS [4]. Tse et al. have grouped these risk factors into four categories; pharmacological, environmental factors, demographic details and genetic background [3]. Although the precise incidence rates varied slightly by treatment setting and country there is limited evidence to suggest that these are significant risk factors in the development of NMS [3].

The pharmacological risk most commonly relates to treatment with antipsychotic medication or following withdrawal of dopaminergic agents [1,5]. Several aspects of antipsychotic treatments have been found to contribute to the risk of developing NMS, including high dosages, dose increases and the early phases of antipsychotic treatment. Parenteral administration, combining antipsychotic agents and polypharmacy have also been associated with an increased risk, but there is no conclusive evidence that using either typical or atypical antipsychotics contributes greater risk [3,6].

Environmental factors relate to dehydration and high core temperatures as well as physical restraint. Advancing age appears to be a contributing factor and the average age of patients with NMS has been found to be 46.9 years [4]. There also seems to be a potential genetic link as patients with previous episodes are more likely to experience a recurrence, as are those with a family history of NMS [7]. Similarly, patients with a previous history or family history of catatonic syndrome also have an increased risk of NMS and there is evidence of a potential overlap between these syndromes [8]. Indeed, three subtypes of NMS have been proposed based on catatonic features; those in whom catatonic symptoms precede onset of NMS, concurrent NMS and catatonic symptoms and those with NMS without catatonia [9]. While the sample size was too small determine definitive differences in clinical course, risk factors or demographics between subtypes, further case reports have suggested that NMS with catatonia may be a benzodiazepine responsive subtype [10], while other studies have demonstrated symptom overlap between non-catatonic NMS and serotonin syndrome [11]. A systematic review of case reports also demonstrated that NMS associated with atypical antipsychotics may present with atypical features such as fewer extrapyramidal symptoms, although the presence of catatonia was not examined [12].

Recognition and Diagnostic Criteria

A lack of definitive diagnostic criteria for NMS may severely hamper recognition of a condition with serious consequences, where early treatment can be lifesaving [13]. There are numerous diagnostic criteria that have been suggested for NMS with small but important variations between them [14-20]. Differences have centred on exact measurements of temperature, heart rate, blood pressure and creatine kinase required for NMS diagnosis and the relative importance of each criterion. Gurrera et al. [19] have attempted to address this issue by developing, an International Expert Consensus (IEC) on NMS criteria. As well as defining the critical values and specific criteria necessary for a diagnosis of NMS, these criteria include a weighted scale, giving varying importance to each criterion out of a total 100 points [21]. More recently, IEC criteria have been validated against previous records of NMS diagnoses, in order to generate potential cut-offs scores which could be used to diagnose NMS [21]. This study found that a cut-off score of 74 gave sensitivity 69.6% and specificity 90.7% compared to modified Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. While the absence of an objective biological marker to confirm NMS makes it impossible to compare criteria for diagnostic accuracy, the principle behind the IEC criteria appears to be a promising tool both for NMS and potentially other psychiatric conditions.

Management and Antipsychotic Re-Challenge

The management of NMS remains primarily supportive and includes the immediate discontinue of the antipsychotic agent, monitoring of vital signs, fluid resuscitation, correction of electrolyte imbalances, cooling and removal of restraint [1,22,23]. Additionally, there is well documented evidence for the effectiveness of pharmacological agents such as benzodiazepines, dantrolene, bromocriptine and amantadine in the management of NMS. Electro-Convulsive Therapy (ECT) can also be used in severe cases that have not responded to medication, with good evidence of recovery from NMS and some control of psychiatric symptoms [24]. However, the reintroduction of antipsychotics in a patient who has experienced NMS is particularly challenging as guidelines are lacking and evidence is reliant upon case reports or series in which longer term outcomes are seldom reported [1]. Ideally the reintroduction of antipsychotics should be avoided, but in patients with chronic psychotic illness this is unlikely to be a feasible strategy and

*Corresponding author: Tobias Rowland, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK; Tel: +447957247180; E-mail: T.rowland.2@warwick.ac.uk

Received: September 25, 2018; Accepted: October 05, 2018; Published: October 12, 2018

Citation: Rowland T, Beyers C (2018) Neuroleptic Malignant Syndrome: A Focus on Risk, Recognition and Antipsychotic Re-Challenge. Prim Health Care 8: 310. doi: 10.4172/2167-1079.1000310

Copyright: © 2018 Rowland T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
careful consideration of the risks and benefits of antipsychotics needs to be considered in each individual case.

The recurrence rates of NMS in those restarted on antipsychotics vary from 13-37% [25,26], although the majority of patients can continue on antipsychotics safely. A number of principles are apparent from the best literature evidence, which suggest that a "washout" period between the resolution of NMS symptoms and the reintroduction of an antipsychotic agent may be important, with advice ranging from 3-14 days [25,27,28]. Most studies switched to a different antipsychotic for re-challenge and the use of an atypical agent with low D2 receptor affinity such as Quetiapine [29], Olanzapine [30,31] or Clozapine [32,33] is recommended [1,34], while successful re-challenge with Aripiprazole, a partial agonist at D2 receptors, has also been reported [13,35]. However, notable case series did not find recurrence was related to the medication used [25,27]. Additionally, there are reports of successful re-challenge with the same antipsychotic medication, usually Clozapine, where patients with treatment resistant illness were unable to be successfully treated with alternative antipsychotics [32,36,37]. A low starting dose of antipsychotic medication with careful titration and monitoring while informing patients and carers about the key features of NMS are other important aspects of antipsychotic reintroduction strategy [1,34], while avoiding the use of depot or parenteral antipsychotics [22].

**Conclusion**

In conclusion, NMS is an uncommon but life threatening condition which requires early recognition and immediate medical management. Diagnosis remains challenging due to multiple criteria, but attempts are being made refined and standardise these. It is inevitable that due to the patient group receiving antipsychotics, many will require reintroduction of medication, although this should always be considered a risk-benefit decision on an individual basis, involving patients and carers in the discussion wherever possible. Current recommendations from the literature are to allow 14 days after resolution of symptoms before reintroducing antipsychotics, to restart reintroduction strategy [1,34], while avoiding the use of depot or parenteral antipsychotics [22].

**References**

1. Pileggi DJ, Cook AM (2016) Neuroleptic malignant syndrome. Ann Pharmacother 50: 973-981.
2. Modi S, Dharaiya D, Schultz L, Varelas P (2016) Neuroleptic malignant syndrome: Complications, outcomes and mortality. Neurocritical care 24: 97-103.
3. Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F (2015) Neuroleptic malignant syndrome: A review from a clinically oriented perspective. Curr Neuropsychopharmacol 13: 395-406.
4. Sahin A, Ciccek M, Gomenc Cekic O, Gunaydin M, Aykut DS, et al. (2017) A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality. Turk J Emerg Med 17: 141-145.
5. Keyser DL, Rodnitzky RL (1991) Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med 151: 794-796.
6. Su YP, Chang CK, Hayes RD, Harrison S, Lee W, et al. (2014) Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta psychiatr Scand 130: 62-60.
7. Otani K, Horuchi M, Kondo T, Kaneko S, Fukushima Y (1991) Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 158: 850-853.
8. Lang FU, Lang S, Becker T, Jäger M (2015) Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology (Berl) 232: 1-5.
9. Lee JW (2007) Catatonic variants, hyperthermic extrapyramidal reactions and subtypes of neuroleptic malignant syndrome. Ann Clin Psychiatry 19: 9-16.
10. Miyaoa H, Shishikura K, Otsubo T, Muramatsu D, Kamijima K (1997) Diazepam-responsive neuroleptic malignant syndrome: a diagnostic subtype? Am J Psychiatry 154: 882.
11. Carroll BT, Lee JW, Graham KT, Thalassinos A, Thomas C, et al. (2008) Diagnosing subtypes of neuroleptic malignant syndrome: An introduction to the Lee-Carroll Scale. Ann Clin Psychiatry 20: 47-48.
12. Belvederi Murri M, Guaglianone A, Bugliani M, Calacagni P, Respino M, et al. (2015) Second-generation antipsychotics and neuroleptic malignant syndrome: Systematic review and case report analysis. Drugs R D 15: 45-62.
13. Rowland TA, Banga A, Aydural N (2018) Neuroleptic malignant syndrome: The value of diagnostic criteria. Prim Care Companion CNS Disord 20: 1-4.
14. Levenson JL (1985) Neuroleptic malignant syndrome. Am J Psychiatry 142: 1137-1145.
15. Addonizio G, Suwan VL, Roth SD (1986) Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 143: 1597-1599.
16. Pope HG Jr, Keck PE Jr, McElroy SL (1986) Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 143: 1227-1233.
17. Friedman JH, Davis R, Wagner RL (1988) Neuroleptic malignant syndrome. The results of a 6-month prospective study of incidence in a state psychiatric hospital. Clin Neuropharmacol 11: 373-377.
18. Mathews T, Aderibigbe YA (1999) Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 2: 1-11.
19. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, et al. (2011) An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72: 1222-1228.
20. Fond G, Godin O, Brunel L, Aouizerate B, Berna F, et al. (2016) Peripheral sub-infarction is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. J Affect Disord 191: 209-215.
21. Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN (2017) A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol 37: 67-71.
22. Olmsted TR (1988) Neuroleptic malignant syndrome: Guidelines for treatment and reinstitution of neuroleptics. South Med J 81: 888-891.
23. Woodbury MM, Woodbury MA (1992) Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 31: 1161-1164.
24. Trolor JN, Sachdev PS (1999) Electroconvulsive treatment of neuroleptic malignant syndrome: A review and report of cases. Aust N Z J Psychiatry 33: 650-659.
25. Wells AJ, Sommi RW, Crinson ML (1988) Neuroleptic rechallenge after neuroleptic malignant syndrome: Case report and literature review. Drug Intell Clin Pharm 22: 475-480.
26. Caroff SN, Mann SC (1993) Neuroleptic malignant syndrome. Med Clin North Am 77: 185-202.
27. Rosebush PI, Stewart TD, Gelenberg AJ (1989) Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 50: 295-298.
28. Velamoor VR (1998) Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf 19: 73-82.
29. Patel K, Lilly B, Ajayi O, Melvin K (2018) A case of neuroleptic malignant syndrome in a profoundly intellectually disabled patient with successful reintroduction of antipsychotic therapy with quetiapine. Case Rep Psychiatry 2018: 7045106.
30. Mendhekar DN, Jiloha RC, Mehdiratta MM, War L (2002) Challenge with atypical antipsychotic drugs in risperidone induced neuroleptic malignant syndrome: A case report. Indian J Psychiatry 44: 387-390.
31. Grignon S, Ianc Brethes J, Chamberland M, Guimaraes DB (2005) Incipient olanzapine. Int J Psychiatry Clin Pract 9: 296-298.
32. Anbalagan E, Ithman M, Lauriello J (2014) Rechallenging clozapine after neuroleptic malignant syndrome. Psychiatr Q 85: 345-348.

33. Weller M, Kornhuber J (1992) Clozapine rechallenge after an episode of ‘neuroleptic malignant syndrome’. Br J Psychiatry 161: 855-856.

34. Sarkar S, Gupta N (2017) Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association. BJPsych Bull 41: 211-216.

35. Trutia A, Bledowski J, Pandurangi A, Kahn DA (2008) Neuroleptic rechallenge with aripiprazole in a patient with previously documented neuroleptic malignant syndrome. J Psychiatr Pract 14: 398-402.

36. Chatterton R, Cardy S, Schramm TM (1996) Neuroleptic malignant syndrome and clozapine monotherapy. Aust N Z J Psychiatry 30: 692-693.

37. Huang TL (2001) Neuroleptic malignant syndrome associated with long-term clozapine treatment: Report of a case and results of a clozapine rechallenge. Chang Gung Med J 24: 522-525.